Celldex Therapeutics, Inc. (CLDX)
| Market Cap | 3.06B +87.5% |
| Revenue (ttm) | 158,000 -97.3% |
| Net Income | -300.55M |
| EPS | -4.33 |
| Shares Out | 78.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,278,872 |
| Open | 39.47 |
| Previous Close | 38.71 |
| Day's Range | 38.92 - 40.66 |
| 52-Week Range | 22.10 - 45.14 |
| Beta | 0.84 |
| Analysts | Strong Buy |
| Price Target | 59.07 (+51.54%) |
| Earnings Date | Aug 6, 2026 |
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias,... [Read more]
Financial Performance
In 2025, Celldex Therapeutics's revenue was $1.55 million, a decrease of -77.99% compared to the previous year's $7.02 million. Losses were -$258.76 million, 63.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for CLDX stock is "Strong Buy." The 12-month stock price target is $59.07, which is an increase of 51.54% from the latest price.
News
Celldex Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Barzolvolimab is advancing through large phase III trials for CSU and related conditions, with a differentiated mechanism targeting mast cells and a strong safety profile. The company is preparing for commercial launch, expanding its pipeline, and expects market growth as new therapies accelerate diagnosis and treatment.
Celldex price target raised to $50 from $46 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Celldex (CLDX) to $50 from $46 and keeps an Overweight rating on the shares ahead of topline data from…
Celldex to Present at Upcoming Investor Conference
HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Septe...
Celldex price target raised to $46 from $40 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Celldex (CLDX) to $46 from $40 and keeps an Overweight rating on the shares.
Celldex price target raised to $53 from $48 at Barclays
Barclays raised the firm’s price target on Celldex (CLDX) to $53 from $48 and keeps an Overweight rating on the shares post the Q2 report. The firm is positive on…
Celldex Therapeutics Earnings release: Q2 2026
Celldex Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Celldex Therapeutics Quarterly report: Q2 2026
Celldex Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Celldex Therapeutics Slides: Corporate presentation
Celldex Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Celldex price target raised to $72 from $48 at Wells Fargo
Wells Fargo raised the firm’s price target on Celldex (CLDX) to $72 from $48 and keeps an Overweight rating on the shares. While the Street is modeling a high probability…
Celldex price target lowered to $61 from $67 at Cantor Fitzgerald
Cantor Fitzgerald lowered the firm’s price target on Celldex (CLDX) to $61 from $67 and keeps an Overweight rating on the shares. Celldex’s Phase 2 barzolvolimab trial in prurigo nodularis…
Celldex price target lowered to $48 from $54 at Wells Fargo
Wells Fargo lowered the firm’s price target on Celldex (CLDX) to $48 from $54 and keeps an Overweight rating on the shares. While the firm removes PN from its model,…
Celldex price target lowered to $40 from $44 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Celldex (CLDX) to $40 from $44 and keeps an Overweight rating on the shares after the Phase 2 study of barzolvolimab in…
Celldex price target lowered to $60 from $62 at Canaccord
Canaccord lowered the firm’s price target on Celldex (CLDX) to $60 from $62 and keeps a Buy rating on the shares. The firm updated its model after the company reported…
Celldex price target lowered to $70 from $78 at Leerink
Leerink lowered the firm’s price target on Celldex (CLDX) to $70 from $78 and keeps an Outperform rating on the shares.
Celldex to stop skin disease study after trial setback
Celldex Therapeutics said on Tuesday it would discontinue the development of its experimental drug for a skin disease after it failed to meet the main goal and key secondary goals in a mid-stage stu...
Celldex Therapeutics Transcript: Study result
Barzolvolimab failed to show efficacy in reducing itch or skin lesions in phase II PN, despite achieving strong mast cell depletion and maintaining a favorable safety profile. The study is discontinued for PN, but ongoing trials in other indications remain on track.
Celldex Therapeutics Press release: Study result
Celldex Therapeutics issued a press release on July 21, 2026, disclosing material business information to investors.
Celldex Therapeutics Slides: Study result
Celldex Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2026.
Celldex reports barzolvolimab study did not meet primary, secondary endpoints
Celldex (CLDX) reported topline results from the company’s Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis, a chronic skin disease that causes hard, intensely itchy lumps/...
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
HAMPTON, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported topline results from the Company's Phase 2 study of barzolvolimab delivered subcutaneously in prurigo nodularis (P...
Celldex price target raised to $100 from $90 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Celldex (CLDX) to $100 from $90 and keeps a Buy rating on the shares. Ahead of the pivotal EMBARQ-CSU1/2 topline…
Celldex CFO Sam Martin to retire in 2027
Celldex (CLDX) announced that Sam Martin, senior VP and CFO, has informed the company of his plans to retire in 2027. Martin has served as the company’s CFO since 2017…
Celldex Announces Planned Transition of Chief Financial Officer
HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to reti...
Celldex Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and approved all four proposals, including director elections, auditor ratification, equity plan amendment, and executive compensation. Strategic updates highlighted strong cash reserves, pipeline progress, and upcoming clinical milestones.
Celldex presents long-term results from Phase 2 study of barzolvolimab
Celldex (CLDX) announced the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology, EAACI,…